The global type 2 diabetes epidemic is increasing.
1 Although there have been improvements in long-term outcomes, the excess mortality and cardiovascular morbidity remain a considerable challenge for health care systems.
2 Several drug classes have emerged that are efficacious in improving glycemic control. These include the incretin-based therapies: dipeptidyl peptidase 4 (DPP-4) inhibitors and glucagon-like peptide 1 (GLP-1) agonists,
3 and sodium-glucose cotransporter 2 (SGLT-2) inhibitors. International guidelines recommend escalation to either SGLT-2 inhibitors or incretin-based treatments in people with type 2 diabetes not achieving target glycemic control with metformin.
4,5